Doctors heal wounds like his with collagen sheets.
I make the collagen in those sheets.
Parth Shinde. Avenyx Bio, Kobe. Scroll, swipe or use the arrow keys.
Integra sells this a year. It began with one collagen sheet, made from cow tendon.
Medicare pays for each cm² of sheet since 2026. Integra got $27 before.
210 days to FDA clearance for MatriDerm, a collagen wound sheet that matched one already sold.
to make one gram.
gross margin at ₹350 a gram.
batch to batch, across nine batches.
Tap any material, market or company to trace its path. Tap again, or reset, to see all.
Stryker, J&J, Zimmer Biomet, Smith+Nephew, Globus. Today I reach $0.5B of it: cartilage and tendon.
Nine sellers, from Solventum to Hartmann. Today I reach $7.7B of it.
AbbVie and Galderma. Today I reach $2.1B: fillers and biostimulators.
Straumann, Envista, Dentsply Sirona. Today I reach $0.9B: regeneratives.
Baxter and BD. Today I reach $1.2B: hemostats.
Each new material and each new tissue moves me further in. The whole market grew about 4% in 2025, organic, by its sellers' own reports.
2025 revenue each seller reports. Companies that do not report a figure are left out, so this is a floor. Wound care sellers in 2026: US skin substitute makers are falling after the Medicare reset.
One collagen tendon implant. Smith+Nephew bought it in 2017.
$125M upfront plus up to $85M over five years. FDA cleared it in 2014, three years before.
Fish skin, a by-product. Coloplast bought it in 2023.
Up to $1.3B, $1.2B upfront. Revenue DKK 510M in the year to Sep 2022, about 17 times. 98% of sales in the US.
One tissue sheet, AlloDerm. Allergan bought it in 2017.
KCI first bought LifeCell for $1.7B in 2008, when it made $190.5M a year. Allergan paid $2.9B in 2017, when it made about $450M a year.
Integra began with one collagen plant. I begin with the material.
Labs and device makers buy grams. Cash comes in from the first batch.
Makers run it in their own plants. I earn on every product they sell.
Today, collagen. Next, every native material in the body.
Parth Shinde. parth@avenyx.bio